# United Therapeutics Corporation (UTHR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $487.61, market value $20.9 billion.

## Valuation
- **P/E (trailing): 17.5×** (5-yr avg 16.6×, 3-yr avg 14.3×). United Therapeutics Corporation trades at 17.5× trailing earnings, close to its own five-year average of 16.6×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 16.2×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.24**. A PEG of 1.24 is in the range usually read as fairly priced for its growth.
- **Price / sales: 6.6×**. Each dollar of revenue is priced at 6.6×.
- **Price / book: 3.3×**. The shares trade at 3.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 5.2%** (5-yr avg 5.4%). Free cash flow equals 5.2% of the market value, in line with its five-year average of 5.4%. Above 5% is generally attractive.
- **Earnings yield: 5.7%**. The inverse of the P/E: 5.7% of the price is earned each year.

## Profitability
- **Gross margin: 86.1%**. United Therapeutics Corporation keeps 86.1% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 44.4%**. 44.4% of revenue is left after running the business, an exceptional level.
- **Net margin: 41.9%**. 41.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 18.8%**. 18.8% on shareholders' equity is solid.
- **Return on assets: 16.6%**. Each dollar of assets produces 16.6% of profit.

## Growth
- **Revenue growth (1 yr): 10.6%** (3-yr 18.0%/yr, 5-yr 16.5%/yr). Revenue grew 10.6% over the last year, against 16.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 13.1%** (3-yr 22.9%/yr, 5-yr 19.3%/yr). Earnings per share rose 13.1%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 16.2%/yr**. Free cash flow has compounded at 16.2% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Current ratio: 6.60** (quick 6.60). Current assets cover the next year's liabilities 6.60 times.
- **Altman Z-score: 18.78**. A Z-score of 18.78 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. United Therapeutics Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (12 analysts). 12 analysts cover United Therapeutics Corporation; the consensus is buy, with an average price target of $664.33 (+36% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 28.2%** (YTD 0.1%, 3-mo -11.3%). The shares are up 28.2% over twelve months including dividends.
- **From 52-week high: -20.0%** (24.3% above the low). Trading 20% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 35**. An RSI of 35 is neutral.
- **Beta (1 yr): 0.10** (volatility 33%). Beta of 0.10 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=UTHR · Page: https://foliofundamentals.com/stocks/uthr

Not investment advice.